Neurodegenerative disease management, 2016-02, Vol.6 (1), p.5-12
2016
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- Changes in brain atrophy indices in patients with relapsing-remitting multiple sclerosis treated with natalizumab
- Ist Teil von
- Neurodegenerative disease management, 2016-02, Vol.6 (1), p.5-12
- Ort / Verlag
- England: Future Medicine Ltd
- Erscheinungsjahr
- 2016
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- To evaluate the effect of natalizumab on progression of brain atrophy in multiple sclerosis (MS) patients and to search for a clinical or radiological marker of progression of brain atrophy. We retrospectively recorded demographic and clinical data, as well as the corpus callosum index (CCI) using MRI, in MS patients treated with natalizumab for 1-4 years. In the study population (n = 29), baseline mean CCI was 0.37 ± 0.04 and final CCI 0.36 ± 0.04. 17 patients did not develop brain atrophy during follow-up. There was no statistically significant relationship between progression of atrophy and clinical and radiological parameters. Natalizumab may have a neuroprotective effect.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 1758-2024eISSN: 1758-2032DOI: 10.2217/nmt.15.53Titel-ID: cdi_proquest_journals_2341586072
- Format
- –
- Schlagworte
- Adult, Age, Atrophy, Atrophy - complications, Atrophy - prevention & control, Brain - drug effects, Brain - pathology, brain atrophy, Clinical medicine, Clinical trials, Corpus Callosum - drug effects, Corpus Callosum - pathology, corpus callosum index, Disease Progression, Female, Humans, Immunologic Factors - administration & dosage, Immunologic Factors - therapeutic use, Immunotherapy, Inflammation, Magnetic resonance imaging, Male, Middle Aged, Monoclonal antibodies, Multiple sclerosis, Multiple Sclerosis, Relapsing-Remitting - complications, Multiple Sclerosis, Relapsing-Remitting - drug therapy, natalizumab, Natalizumab - administration & dosage, Natalizumab - therapeutic use, Neurodegeneration, Patients, Retrospective Studies